Articles by Rory Budihandojo - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe
  • Search
  • Suppliers
  • Careers

Enter a company or product name

Keyword Location
About Search
Articles by Rory Budihandojo

Rory Budihandojo


Rory Budihandojo is a computer validation manager at Boehinger-Ingelheim, 2820 N. Normandy Dr., Petersburg, VA 23805, tel. 804.504.8373, fax 804.504.8637, rbudihandojo@bichemicals.com. He is also a member of Pharmaceutical Technology's Editorial Advisory Board.
Articles
A Path to Quality
July 2, 2008
By: Rory Budihandojo

A new book explains process analytical technology, drug stability, and quality.
A Perspective on Computer Validation
July 2, 2007
By: Rory Budihandojo , Steve Coates , Ludwig Huber , Jose E. Matos , Siegfried Schmitt , David Stokes , Graham Tinsley , Maribel Rios

This article provides a historical review of computer validation in the pharmaceutical industry within the last three decades, evolving from the early years' initial concept and approach to today's current practices. Also included is how the regulations and industry have progressed in addressing the topic of computer validation.
The Future State of Computer Validation, Part II: Increasing the Efficiency of Computer Validation Practices
September 2, 2001
By: Rory Budihandojo

The authors forecast how the current industry events and trends will affect computer validation in the future.
The Future State of compter Validation, Part I
July 1, 2001
By: Rory Budihandojo

Current events and trends in regulations, business practices, and technology forecast the future of computer validation.

ADVERTISEMENT
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
How does your company apply quality-by-design (QbD) principles to manufacturing processes?
To all processes for both new and legacy products
To all process for new products only
To select process for new products only
To select processes for both new and legacy products
Do not use QbD
To all processes for both new and legacy products
20%
To all process for new products only
13%
To select process for new products only
24%
To select processes for both new and legacy products
20%
Do not use QbD
22%
View Results
Eric Langer Outsourcing Outlook Eric LangerOutsourcing's Modest Role as a Cost-Containment Strategy
Patricia Van Arnum Ingredients Insider Patricia Van ArnumIntellectual Property Battles in Solid-State Chemistry
Nathan Jessop Industry Insider Nathan Jessop Campaign Against Counterfeit Drugs Continues
Lynn Torbeck Statistical Solutions Lynn D. TorbeckCompositing Samples and the Risk to Product Quality
 More
FindPharma Custom Search
Featured Jobs

More Jobs
Click here